Abstract 614P
Background
Programmed Death Ligand-1 (PD-L1) is expressed in most type of cancer cells, including osteosarcoma. However, the role of PD-L1 expression in prognosis of osteosarcoma patients remains unclear. Thus, this study aims to investigate the association between PD-L1 expression and prognosis of Osteosarcoma patients.
Methods
Data was gathered from PubMed, PMC, and ScienceDirect databases on September 08, 2022, using keywords associated with PD-L1, Osteosarcoma in relation to the prognosis, which is measured by overall survival (OS), progression free survival (PFS), and event free survival (EFS). Publications included are associated with Osteosarcoma patients that are limited to English manuscripts within the last 10 years. Review articles, publications without full paper, and case report studies are excluded. The quality of each included study was assessed using the Newcastle Ottawa Scale (NOS), JBI Critical Appraisal for Quasi Experimental Studies, and Grading of recommendations, assessment, development, and evaluations (GRADE).
Results
A total of 7 studies consisting of 289 Osteosarcoma patients were included. All 6 studies have good quality based on NOS and one study categorized as include based on JBI. All 7 studies showed that high expression of PD-L1 correlates with poor prognosis of Osteosarcoma patients. Pooled analysis showed that high PD-L1 expression correlates with inferior OS (HR=2.03; 95%CI, 1.12-3.69; p=0.02) and PFS (HR= 1.18; 95%CI, 1.06-1.31; p=0.003). However, no significant association between PD-L1 expression and EFS (HR=1.05; 95%CI, 0.40-2.75; p=0.92). Based on GRADE, the result of this study is moderate in quality, as there is no inconsistency in results and publication biases are minimal.
Conclusions
Current studies demonstrated that high PD-L1 expression is associated with inferior OS and PFS, but not EFS in osteosarcoma patients, which warrants further prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract